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The activity of natural killer (NK) cells is regulated
bysurface receptors,whichdirect target cell rec-
ognition. NKp30 (Natural Cytotoxicity Receptor
3) induces target cell lysis and is also crucial for
the interactionwithdendritic cells. So far, the cel-
lular ligands for NKp30 have remained elusive.
Here we show that the nuclear factor HLA-B-
associated transcript 3 (BAT3) was released
from tumor cells, bound directly to NKp30, and
engaged NKp30 on NK cells. BAT3 triggered
NKp30-mediated cytotoxicity and was neces-
sary for tumor rejection in a multiple myeloma
model. These data identify BAT3 as a cellular
ligand for NKp30. We propose a concept for
target cell recognition byNKcells beyond ‘‘miss-
ing self’’ and ‘‘induced self,’’ mediated through a
tumor cell-derived extracellular factor.
INTRODUCTION
Natural killer (NK) cells are lymphocytes of the innate
immune system, which directly attack tumor and virus-
infected cells. They provide a link between innate and
adaptive immunity through crosstalk with dendritic cells
(DCs) (Moretta et al., 2007; Munz et al., 2005; Walzer
et al., 2005) and mediate T cell activation (Adam et al.,
2005; Hanna et al., 2004; Laouar et al., 2005). The natural
cytotoxicity receptors (NCR) including NKp30, NKp44,
and NKp46 as well as NKG2D are triggering receptors re-
sponsible for NK cell activation (Lanier, 2005; Moretta and
Moretta, 2004). Activating receptors and their corre-
sponding ligands play a vital role for tumor cell recog-
nition and tumor surveillance. A decreased expression of
ligands engaging NCR and NKG2D on tumor cells corre-
lating with impaired tumor recognition and tumor progres-
sion has been reported for both hematological malignan-
cies such as multiple myeloma (Carbone et al., 2005)
and solid tumors (Moretta et al., 2006). The engagementImof NKG2D, moreover, inhibits the formation of chemically
induced sarcomas (Smyth et al., 2005) and the experimen-
tal overexpression of NKG2D-specific ligands on tumor
cells leads to tumor rejection and immunity (Cerwenka
et al., 2001; Diefenbach et al., 2001; Friese et al., 2003).
Until now, little was known about the molecular nature of
the cellular ligands for NKp30, NKp44, and NKp46. These
molecules are so far identified only indirectly by receptor-
specific antibodies that inhibit the NK cell cytotoxicity
against target cells (Bottino et al., 2005; Farag and Cali-
giuri, 2006; Pende et al., 1999).
The orphan NKp30 receptor (NCR3, CD337) plays a
special role because it is the only receptor involved in
both tumor cell lysis and lysis of normal self cells (Ferlazzo
et al., 2002; Pende et al., 1999; Vitale et al., 2005). The
30 kD triggering receptor is selectively expressed on NK
cells and associated with CD3z chains that become phos-
phorylated upon ligation (Pende et al., 1999). Human den-
dritic cells (DCs) express the hitherto unknown NKp30
ligand that mediates the NK-DC interaction, resulting
either in DC activation or DC killing, thus limiting the supply
of dendritic cells (Ferlazzo et al., 2002; Pende et al., 1999;
Vitale et al., 2005). Although the cellular ligands binding to
the NCR receptors are not yet identified, functional data
indicate that they are expressed on cells upon activation,
proliferation, or tumor transformation (Bottino et al., 2005).
So far, it has been unclear why cell lines such as fibro-
blasts or lymphoma cells that are killed by NK cells in
an NKp30-dependent manner fail to bind to soluble
NKp30-Ig fusion proteins (Arnon et al., 2005; Bottino
et al., 2005; Mandelboim et al., 2001; Pende et al., 1999).
Therefore, we used a yeast two-hybrid approach to isolate a
putative NKp30 ligand, which is probably not constitu-
tively expressed on the cell surface. Here we show that
the nuclear factor HLA-B-associated transcript 3 (BAT3)
was released from tumor cell in response to stress signals
and engaged NKp30 on NK cells. Recently it was dis-
covered that nuclear BAT3 is responsible for the p53-
mediated cellular response to stress and DNA damage,
resulting either in DNA repair or in apoptosis, which ulti-
mately suppresses tumor growth (Sasaki et al., 2007).
BAT3 is thus a molecule, which directly links p53 tumormunity 27, 965–974, December 2007 ª2007 Elsevier Inc. 965
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mune system via an activating receptor on NK cells.
RESULTS
BAT3 Is a Direct Binding Partner for NKp30
To identify proteins interacting with NKp30, a fusion con-
struct consisting of the GAL4-DNA-binding domain and
the extracellular NKp30 sequence (GBT9-NKp30) was
used as bait. We screened a K562-derived cDNA library
and isolated a clone encoding the C-terminal sequence
of BAT3 (BAT3-CT). The cDNA fragment of 1.6 kb was
characterized by a deletion of the highly conserved
Bcl-2-associated athanogene (BAG) domain (see Fig-
ure S1A available online). This domain is responsible for
the reported binding of BAT3 to Heat Shock Protein 70
(HSP70) (Takayama et al., 1997; Thress et al., 2001).
Both isoforms, either including or lacking the BAG domain,
are expressed in tumor tissues, cell lines, and monocyte-
derived dendritic cells (Figure S1B). Analysis of BAT3 (full-
length) and a panel of deletion constructs showed that the
1.6 kb C-terminal fragment was necessary and sufficient
for the direct binding to NKp30, irrespective of the BAG
domain. The NKp30 binding, however, may include a di-
merization of BAT3 molecules, as indicated by the fact
that a BAT3-BAT3 interaction was observed (Figure S1A).
Several control constructs that failed to interact with
BAT3 or NKp30, respectively, were used to prove the
specificity of the two-hybrid results (noted in the legend
to Figure S1A).
The direct and specific binding of NKp30 to BAT3 was
confirmed by coimmunoprecipitation. Wild-type 293T
cells (WT) and a 293T cell line that constitutively ex-
pressed the extracellular domain of NKp30 fused to the
Fc sequence of human IgG1 (NKp30-Ig; Figure S1C)
were transfected with BAT3-CT or BAT3 expression con-
structs encoding histidine-tagged proteins. Both BAT3
constructs were coprecipitated by isolation of NKp30-Ig
from the transfected cells with protein-G sepharose that
binds to Fc sequence (Figure 1). No unspecific precipita-
tion was detectable in extracts of cells transfected with
CD30-Ig (not shown), wild-type cells, or in cells over-
expressing the control protein hepatocyte nuclear factor
4 (HNF4) (Figure 1, left lane). These experiments proved
the specificity of the BAT3-NKp30 interaction in mamma-
lian cells and further supported the idea that BAT3 is
a putative ligand for NKp30.
The gene encoding human BAT3 was originally identi-
fied within the inflammatory class III region of the human
major histocompatibility locus on chromosome 6 (Banerji
et al., 1990). BAT3 is thus clustered with other immune
regulatory genes such as NKp30, TNF, or LTA. A role for
BAT3 in regulating both proliferation and cell death has
been discussed. BAT3 seems to trigger ricin-induced ap-
optosis (Wu et al., 2004), and BAT3-deficient cells are
more resistant to apoptosis in response to agents affect-
ing the calcium flux in the endoplasmatic reticulum (Des-
mots et al., 2005) or genotoxic stress (Sasaki et al.,
2007). Recently, a gene-depleting approach was used to966 Immunity 27, 965–974, December 2007 ª2007 Elsevier Incshow the precise function: nuclear BAT3 has an essential
role in controlling the acetylation of p53, which is required
for the cellular DNA damage response (Sasaki et al., 2007).
BAT3 Is Released from Tumor Cells
Because a nuclear factor is not accessible for the interac-
tion with the surface receptor NKp30, we tested directly
whether BAT3 was released from tumor cells. 293T cells
were exposed to a nonlethal heat shock and the BAT3 dis-
tribution was monitored in subcellular fractions and the
cell supernatant (Figure 2A). Endogenous BAT3 was pre-
dominantly expressed in the nuclear fraction. However,
it was also detectable in the membrane fractions and
cell supernatants in response to a nonlethal heat shock
(Figure 2A, left). Overexpressed BAT3 was, similarly to
the endogenous protein, detectable in the nuclei. Upon
heat shock, BAT3 was found in the membrane and re-
leased from the cells (Figure 2A, middle). No changes
were observed for the distribution of the nuclear protein
p53 (Figure 2A, right). The number of apoptotic or necrotic
cells was not increased by heat shock (Figure S2C), thus
excluding the possibility that apoptotic or necrotic cells
were the source for BAT3.
Next, the expression pattern of BAT3 upon contact with
NK cells was analyzed. As expected, a transfected histi-
dine-tagged BAT3 protein ((His)6BAT3) was mainly local-
ized in the nuclei of 293T cells (Figures 2B and 2D, red
staining). Upon coincubation with the human NK cell line
NKL (Figure 2C, green staining) or primary NK cells (Fig-
ure 2E), this subcellular expression pattern changed dra-
matically. The nuclear BAT3 staining disappeared and in-
stead staining of the cell membrane became evident. The
Figure 1. Coimmunoprecipitation of BAT3 and NKp30
Wild-type 293T cells (WT) or NKp30-Ig-expressing 293T cells (NKp30)
were transfected with (His)6HNF4 (control), (His)6BAT3-CT (70 kda), or
(His)6BAT3 (>130 kda), and the lysates were analyzed for expression
(a-His Blot, input). The lysates were used for immunoprecipitation
with protein-G sepharose followed by immunoblotting of the eluates
with monoclonal anti-his (a-His) or anti-Ig (a-Ig, eluate). In control
experiments, no protein precipitation was detectable with 293T cells,
which constitutively expressed CD30-Ig or upon transfection of
(His)6HNF4 expression vector (left lane)..
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(A) Immunoblotting to detect BAT3 or p53 in protein extracts (10 mg/
lane) derived from supernatant (sn), membrane (me), or nucleus (nu)
of 293T cells, that were left untreated (0 min HS) or exposed to
a heat shock for the indicated time (min HS, minutes heat shock).
Left, endogenous BAT3; middle, transfected BAT3-CT; right, p53
blot. See Figures S2A and S2B for the BAT3 antiserum (rabbit).
(B–E) (His)6BAT3-transfected 293T cells were grown on coverslips, left
untreated (B, D), or incubated for 2 hr with NKL cells or primary NK cells
(C, E) in the ratio of 1:20 and stained after acetone fixation with a mono-
clonal his antibody and a-mouse-cy3-labeled secondary antibody
(red). (C) shows two examples for a costaining of NKL cells with a
CD30 antibody (anti-CD30-FITC, green), which specifically recognizes
the CD30 surface receptor expressed on NK cells. Cell nuclei were
stained with DAPI (blue). Pictures were acquired with the digital Nikon
Eclipse E800 microscope with the LuciaGF program (Nikon, Du¨ssel-
dorf, Germany) with a 103 NA 0.17 (B, C) or a 603 NA 0.23 objective
(D, E) and processed with Photoshop software (Adobe).
(F and G) Cytospins of (His)6BAT3-transfected 293T were stained after
acetone fixation with a-His-cy3 (a-his) to detect BAT3 (red [F]) and withImsurface expression and/or release of BAT3 are a prerequi-
site for a direct interaction with NKp30 and can thus be re-
garded as a part of tumor cells-NK cell interaction that
leads to NK cell activation and tumor cell lysis. There is
growing evidence that NK cell activation is a two-stage
process, and it was recently demonstrated that NK cell/
tumor cell cocultivation is a crucial step for the activation
(‘‘priming’’) of natural cytotoxicity (North et al., 2007).
To confirm membrane expression, we stained the
plasma membrane with FITC-labeled choleratoxin (FITC-
CtxB). FITC-CtxB specifically stains the lipid ganglioside
GM1 predominantly anchored in the outer leaflet of lipid
raft domains (Harder et al., 1998). Confocal microscopy
scanning revealed expression of BAT3 (Figure 2F, red)
in the plasma membrane compartment, because BAT3
and GM1 appeared partially colocalized (Figure 2G, yel-
low). A similar change in the expression pattern of BAT3
was observed upon exposure to a nonlethal heat shock,
whereas the distribution of a nuclear control protein
((His)6HNF4) remained unchanged (Figure S2D). Taken
together, these results provide evidence that BAT3 is re-
leased from living cells in an inducible manner. BAT3 is
therefore at least transiently accessible for a direct inter-
action with NKp30 expressed on NK cells.
Direct Interaction between Tumor Cell-Derived
BAT3 and NKp30
We next performed experiments to substantiate the claim
that BAT3 was the natural ligand for NKp30. Because a di-
rect binding to NKp30 is a prerequisite for a possible bio-
logical function of released BAT3, the binding properties
of BAT3-enriched supernatant and purified recombinant
BAT3 protein were tested. BAT3 released from tumor cells
is, in contrast to the purified soluble protein, predomi-
nantly detectable in the membrane vesicle fraction (Fig-
ures 3A and 3B) also containing HSP70 and the exosomal
marker LAMP2b.
The in vitro binding of BAT3 to NKp30 was demon-
strated with a BAT3-specific ELISA. A specific binding
to immobilized NKp30-Ig, but not to NKG2D-Ig and
CD30-Ig, was observed for supernatant derived from
BAT3-transfected cells (Figure 3C, black bars) compared
to control supernatant from wild-type cells (Figure 3C,
white bars). The ELISA revealed also a specific binding
of purified BAT3 derived from BAT3-transfected cells (Fig-
ure 3D, black bars) versus control purifications of wild-
type cells (Figure 3D, white bars) to NKp30-Ig. The purified
protein shows also a weak binding to NKG2D-Ig. Because
a direct NKG2D-BAT3 interaction was not observed in
FITC-labeled choleratoxin (Ctx, green), which stains the plasma mem-
brane of 293T cells (merge [G]). Fluorescence images were acquired
by confocal laser scanning microscopy (Leica) with oil objective at pin-
hole size Airy 1. Crosstalk was minimized by serial acquisition of the
fluorescence color channels. The digital images were merged by Leica
LSM software without further processing. 1003 objective lens; NA 1,4;
FITC and cy3 were excited by 488 and 543 nm laser light and emission
was detected at 495–530 nm and 548–700 nm, respectively.munity 27, 965–974, December 2007 ª2007 Elsevier Inc. 967
Immunity
BAT3 Release from Tumor Cells Activates NK CellsFigure 3. Interaction of Tumor Cell-Derived BAT3 with NKp30 on NK Cells
(A) Coomassie staining and immunoblotting of supernatants (SN) and affinity-purified protein (BAT3) derived from BAT3-transfected 293T cells. Load-
ing: 20 ml of a 5-fold concentrated SN and 200 ng of the purified protein for coomassie staining and a 1:10 dilution for immunoblotting. The coomassie
marker (m, lane 3) corresponds to 170 kda, 130 kda, 95 kda, 72 kda, 55 kda, 43 kda.
(B) The supernatant was fractionated by ultracentrifugation to detect BAT3, HSP70, and the exosomal marker LAMP2b in the membrane vesicles and
soluble fraction by immunoblotting (10 mg loaded in each lane).
(C and D) ELISA plates were coated with recombinant NKp30-Ig, NKG2D-Ig, or CD30-Ig (concentration 100 ng/well) followed by incubation with
100 ml BAT3-enriched supernatant from BAT3-transfected 293T cells (black bars), control supernatant from wild-type cells (white bars) (C) or with
5 mg purified BAT3 protein (black bars), or with control purification from wild-type cells (white bars) (D). Binding was detected with anti-BAT3 serum
and anti-rabbit-enzyme linked secondary antibody. Data represent absorbance at 405 nm after normalization to background of nonspecific binding to
the plate. Error bars represent mean and standard deviation (SD) of triplicate samples.
(E) FACS analysis to demonstrate the effect of BAT3-SN on NKp30 mab binding to the human NK line NKL (top histogram) and to fresh NK cells iso-
lated from peripheral blood lymphocytes (NK [PBL]) (middle and bottom histogram). NKL cells and NK (PBL) were left untreated or preincubated with
either control supernatant (SN) or supernatant of BAT3-transfected 293T cells (BAT3-SN) as indicated. Cells were stained with mAb to NKp30. Gray
histograms, background secondary antibody staining; yellow, untreated NK cells; blue, cells blocked with SN; pink, cells blocked with BAT3-SN.
(F) The effect of BAT3-SN on anti-NKp30 binding to fresh NK cells bars indicate the mean fluorescence intensity (MFI). The BAT3-SN- and pp65-me-
diated inhibition (presented for fresh NK cells) is significant (p = 0.012; p = 0.042, respectively; unpaired t test; GraphPadPrism software).
(G) ELISA plates were coated with recombinant NKp30-Ig (concentration 100 ng/well) followed by incubation with BSA (20 mg, filled triangle) or pp65
(20 mg, open triangle). All samples were incubated with recombinant BAT3 (3–25 mg), and binding of BAT3 was detected as described.FACS experiments (not shown), we anticipate that the
binding reflects unspecific protein interactions or might
be attributed to traces of other soluble factors that were
copurified with BAT3.
We also tested whether tumor-cell derived BAT3 (BAT3-
enriched supernatant [BAT3-SN]) was able to bind to
NKp30 on the surface of NK cells. Preincubation of NKL
cells with BAT3-SN, but not with a control supernatant
(Figure 3E, top), blocked the binding of anti-NKp30 (the
preincubation did not interfere with the binding of anti-
NKG2D; not shown). The reproducible inhibition of
NKp30 binding with BAT3-SN was even observed with
fresh NK cells isolated from peripheral blood lymphocytes
that have a low expression of NKp30 (Figure 3E).
Similar binding activity to NKp30 on NK cells was re-
cently reported for pp65, the viral NKp30 ligand (Arnon
et al., 2005). In agreement, the inhibition of anti-NKp30
binding here presented for fresh NK cells was observed
for BAT3-SN and pp65 (Figure 3F). However, blocking
of NKp30 by pp65 did not interfere with BAT3 binding
to plate-bound NKp30-Ig (Figure 3G), suggesting that968 Immunity 27, 965–974, December 2007 ª2007 Elsevier IncBAT3 and pp65 bind to different, not overlapping, NKp30
domains.
These binding studies demonstrated that tumor cell-
derived BAT3 was able to bind to NKp30, and we sub-
sequently analyzed the functional consequences of this
interaction.
BAT3-Mediated Cytokine Release
The secretion of IFN-g and TNF-a from NK cells is crucial
for the reciprocal activation of NK and dendritic cells and
can be mediated through NKp30 (Ferlazzo et al., 2002;
Pende et al., 1999; Vitale et al., 2005). Therefore, we ana-
lyzed the influence of BAT3 on the NK cell-dependent cy-
tokine release (IFN-g, TNF-a). NK cells were incubated for
2 days with medium (med), control supernatant (mock), or
supernatant containing BAT3 (BAT3-SN). The cytokine se-
cretion was stimulated with BAT3-SN, and the stimulation
could be blocked with NKp30- and BAT3-specific anti-
bodies (Figure 4A, left). The blocking was not always com-
plete, particularly for the BAT3 antibodies, suggesting that
factors distinct from BAT3 may also contribute to the NK.
Immunity
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(A) Primary NK cells were incubated for 48 hr with medium (med), supernatant derived either from vector-transfected cells (mock) or from BAT3-trans-
fected 293T cells (BAT3-SN) (left) or with purified protein derived from mock or BAT3-SN, respectively (right). The following antibodies were added as
indicated: 30, NKp30; B, BAT3 (left, chicken; right, rabbit); I, NKp30 isotype; P, rabbit preimmune serum. The NK cell-derived supernatants were
analyzed for IFN-g and TNF-a content by specific ELISA. The means of triplicates and SD (pg/ml) are indicated. One representative experiment of
three is shown.
(B) Primary NK cells were incubated with medium (-) or with a purified control protein DCoH (D) alone and in combination with a DCoH-specific
antiserum (aD) or NKp30 (30), and the supernatants were analyzed for TNF-a and IFN-g.cell activation. Apparently paradoxically, the purified pro-
tein failed to induce any cytokine secretion per se, but
revealed rather an inhibitory effect. Here the coincubation
with BAT3-specific antibodies, which may alter the con-
formation or crosslink-purified recombinant BAT3, resulted
in a strong cytokine release (Figure 4A, right). Control ex-
periments with a purified soluble antigen and a specific
rabbit antiserum revealed that the activation was not
mediated via antigen-antibody complexes, e.g., via CD16
(Figure 4B). Thus, we demonstrated that BAT3 released
from tumor cells (e.g., in membrane vesicles such as exo-
somes) activated NK cells via engaging NKp30, whereas
the purified soluble protein inhibited NK cell-dependent
cytokine release.
Effects of BAT3 Downregulation and BAT3
Overexpression on NK Cell-Dependent Lysis
Third, loss- and gain-of-function experiments were per-
formed to investigate the functional properties of BAT3.
A reduction of the BAT3 mRNA and protein amounts
was achieved after transfection of HeLa cells with the cor-
responding siRNA (Figure 5A). The siRNA-transfected
cells were less efficiently lysed by peripheral blood-
derived NK cells than the control transfected cells (Fig-
ure 5B). The decrease of NK cell-mediated lysis was re-
producible with different donors, although the degree of
inhibition varied. This reflects most likely the varying im-
pact of triggering receptors and their ligands including
NKp30, NKp46, and others depending on their expressionImprofile. Interestingly, the blocking of NKp30-dependent ly-
sis by a masking antibody was less efficient than BAT3
downregulation, particularly when the effector:target ratio
was high (Figure 5B). We speculate that this might be re-
lated to a direct or indirect BAT3-dependent engagement
of triggering receptors distinct from NKp30. Vice versa,
blocking by anti-NKp30 had still minor effects on NK
cell-mediated cytotoxicity of BAT3-siRNA HeLa target
cells. Remaining NKp30-mediated lysis upon BAT3 down-
regulation is not surprising, because siRNA downregula-
tion of BAT3 is not complete (see Figure 5A). In addition,
it cannot be excluded that tumor cells express or coex-
press distinct ligands for NKp30, either on the cell surface
or released, that may interfere.
The overexpression of BAT3 in the colon carcinoma cell
line LS174T induced an enhanced NK cell-mediated lysis
(Figure 5C). This effect was NKp30 mediated, because it
was blocked by preincubating the target cells with the
NKp30-Ig fusion protein in order to block NKp30 ligands.
Taken together, these results suggest that BAT3 is an
activating ligand for NKp30.
BAT3 Is Crucial for NK Cell-Mediated Lysis
In Vitro and In Vivo
Finally, the function of endogenous BAT3 was addressed
in vitro and in vivo. BAT3 antibodies that were able to ef-
fectively deplete BAT3 from the cell supernatant (Fig-
ure 6A) were used to inhibit the NKp30-dependent lysis
of Raji cells (Figure 6B). Best results were obtained withmunity 27, 965–974, December 2007 ª2007 Elsevier Inc. 969
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(A) Downregulation of BAT3 expression in HeLa cells. HeLa cells were transfected with control siRNA or BAT3-siRNA, and mRNA was isolated and
analyzed for BAT3 and GAPDH expression by RT-PCR with gene-specific primers. BAT3-specific primers flank the BAG domain, and isoforms either
lacking or including the BAG domain were detected (PCR products: 311 nt and 450 nt, respectively). Total protein lysates were prepared and analyzed
for BAT3 and actin expression by specific immunoblotting. m, molecular weight marker; H2O, control lacking cDNA; si, BAT3-siRNA; ctr, control.
(B) NK cell-mediated lysis of HeLa cells. HeLa cells transfected either with si control RNA or with BAT3-siRNA were incubated with primary NK cells
at different effector:target ratios, and the lysis of the target cells was determined in an europium release assay. An isotype and an NKp30 antibody
were used to block lysis of the target cells, and the NKp30-mab dependent lysis inhibition of BAT3-wild-type cells is indicated. The decrease of cell
lysis upon BAT3 downregulation is significant (p = 0.0063; paired t test, one tailed, GraphPadPrism software).
(C) Primary NK cell lysis of LS174T cells transfected with vector or BAT3-CT. LS174T cells were transfected with a control vector or a BAT3 expression
vector. The target cells were preincubated with NKp30-Ig (15 mg ml1) prior lysis to block NKp30 ligands as indicated. Effector and target cells were
coincubated at different effector:target ratios. The increase of cell lysis is significant for BAT3-CT-transfected cells compared to vector-transfected
cells (p = 0.0074), only if NKp30 ligands are not blocked with NKp30-Ig (paired t test, one-tailed, GraphPadPrism software). Error bars represent mean
± SD of triplicate samples. CD30-Ig used as a control did not alter sensitivity of vector- or BAT3-CT-transfected cells and no differences in lysis were
observed for untransfected versus vector-transfected target cells (not shown). One representative experiment of three is shown (B, C).an unusual long incubation period for the europium re-
lease assay (14 hr). This has also been described for the
inhibition of NKp30 lysis by its viral ligand pp65 (Arnon
et al., 2005).
Subsequently, we monitored the growth of RPMI8226-
derived tumors in nude mice in the presence of human pe-
ripheral blood lymphocytes (PBL), either with a control an-
tiserum (rabbit) or with blocking BAT3-specific antiserum
(Figure 6C). The rapid growth of subcutaneous tumors
(8/10) could be suppressed completely by treatment with
human PBLs (0/10). In contrast, the simultaneous injection
of BAT3-specific antibodies resulted in a decreased tumor
rejection (6/10), indicating that BAT3 is crucial for tumor cell
recognition and killing in this model.
DISCUSSION
In this study, we have shown that BAT3 may serve as a cel-
lular ligand for NKp30 because (1) BAT3 binds directly to970 Immunity 27, 965–974, December 2007 ª2007 Elsevier IncNKp30, (2) BAT3 inhibition or overexpression reduces or
enhances NK cell-mediated killing, respectively, (3) re-
leased BAT3 triggers cytokine secretion of NK cells
(TNF-a, IFN-g), and (4) BAT3 mediates tumor rejection in
a multiple myeloma xenograft model.
BAT3 is structurally characterized by C-terminal nuclear
localization signals, an N-terminal ubiquitin-like region,
a polyproline stretch, and the conserved BAG (Bcl-asso-
ciated anthogene) domain that interacts with HSP70
(Manchen and Hubberstey, 2001; Takayama et al., 1997;
Thress et al., 2001). Thus, BAT3, as a nuclear factor, is
not reminiscent of a classical ligand. The protein also lacks
any leader sequences targeting it to the classical secretion
pathways. The data presented here demonstrate that BAT3
is released from tumor cells and may then interact with
NKp30 on the surface of NK cells.
The possibility that NKp30 might have intracellular li-
gands was raised for the first time by Arnon et al. (2005).
They recently identified the viral NKp30 ligand pp65 from.
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a general suppression of the NK cell activity through a spe-
cific and direct interaction with NKp30 (Arnon et al., 2005).
The viral factor pp65 has no structural homology to BAT3,
but is like BAT3 localized in the cell nuclei (of infected
cells). Therefore, it is unclear where and when pp65 inter-
acts with NKp30 in vivo, and it has been speculated that
soluble pp65 derived from the direct lysis of virus-infected
Figure 6. In Vivo Activity of BAT3
(A) Two BAT3-specific rabbit antisera were used in a 1:5000 dilution to
deplete BAT3 from 293T-derived supernatants. SN-depl2 was chosen
for further experiments.
(B) Raji cells were incubated with primary NK cells for 14 hr at different
effector:target ratios without competing antibodies (alone) or with an
rabbit preimmune serum (rabbit control), anti-NKp30, and anti-BAT3.
The percent lysis was determined in a europium release assay.
(C) CD1 nude mice received 5 3 106 RPMI8226 cells subcutanously
alone (RPMI8226) or in combination with 5 3 106 human peripheral
blood lymphocytes that were mixed 5:1 with either 40 ml control rabbit
antiserum (RPMI8226+PBL+ control) or 40 ml BAT3-specific antiserum
(RPMI8226+PBL+aBAT3). The tumor volume at day 13 and 20 for
each animal is indicated. Data from two independent experiments
with five animals in each group are shown. The difference between
RPMI8226+PBL+control versus RPMI8226+PBL+aBAT is significant
(p = 0.0168, day 20) (paired t test, one tailed, GraphPadPrism soft-
ware).Imcells or from apoptotic cells may bind to NKp30 (Arnon
et al., 2005). However, the data presented here suggest
a different mode of action for the release of the cellular li-
gand. We assume that active mechanisms, e.g., a modifi-
cation of BAT3, might be involved, because BAT3 release
from living cells was shown.
The BAT3-binding protein HSP70 is known as a potent
stimulator that triggers the activity of NK cells, when ex-
pressed on the cell surface or upon secretion (Asea
et al., 2000; Gastpar et al., 2005; Gehrmann et al., 2005;
Millar et al., 2003). Although the mechanisms underlying
the release of BAT3 remain to be elucidated, it is tempting
to speculate that the transport is associated with exo-
somes, as described for HSP70 (Gastpar et al., 2005;
Radons and Multhoff, 2005). In fact, a high molecular pro-
tein complex containing BAT3 and HSP70 was purified
from 293T cells (unpublished data), and BAT3 was detect-
able in the membrane vesicles fraction of 293T-derived
supernatant.
An exosomal release of BAT3 would also explain why
BAT3-enriched supernatant derived from tumor cells stim-
ulated the NK cell-mediated cytokine release, whereas
the purified, recombinant protein acted in a rather
suppressive manner. Opposite biological effects for mem-
brane-expressed versus soluble factors is not an unusual
observation for ligands engaging a triggering NK cell re-
ceptor. Surface expression of MICA (major histocompati-
bility complex class I chain-related gene A), a NKG2D-spe-
cific ligand, marks transformed cells for destruction by
immune effector cells, whereas soluble ligands directly in-
hibit NKG2D-mediated activation and may promote tumor
cell escape from immunosurveillance (Groh et al., 2002;
Bottino et al., 2005).
Our functional in vivo findings on BAT3 were reminis-
cent to heat shock proteins. HSP70, a multifunctional fac-
tor acting as a chaperone or cytokine, can induce tumor
rejection when purified from the tumor (Calderwood
et al., 2005; Millar et al., 2003). Interestingly, it has been
reported that nuclear protein complexes that contain
HSPc70 together with high mobility group (HMG) proteins
B1 and B2 and with BAT3 and HSPc70 are involved in the
cytotoxic response to DNA damage (Krynetski et al.,
2003). HMGB1 is, so far, the best characterized nuclear
factor, which exhibits cytokine activity upon release, and
this factor is mainly involved in NK-cell mediated matura-
tion of dendritic cells (Lotze and Tracey, 2005; Semino
et al., 2005). HMGB1 is thought to transduce its function
through Toll-like receptors (TLR 2 and 4) and receptor of
advanced glycation end products (RAGE), although other
not-yet-identified receptors might be involved.
It is conceivable that such nuclear proteins, which ex-
hibit cytokine function to alert the immune system, are
sensors for DNA instability or damage of transformed
cells. This model is supported by the exciting finding
that BAT3 is crucial for the p53 acetylation (Sasaki et al.,
2007), a central event for the cellular DNA damage re-
sponse. A direct link of the DNA damage response to in-
nate immunity and cancer was recently discovered by
Gasser et al. (2005), demonstrating that the DNA damagemunity 27, 965–974, December 2007 ª2007 Elsevier Inc. 971
Immunity
BAT3 Release from Tumor Cells Activates NK Cellspathway directly regulated the expression of ligands en-
gaging the NKG2D receptor.
Factors such as HSP70, HMGB1, and BAT3 are emerg-
ing as a class of immune regulatory proteins, which may
be regarded as an intracellular subgroup of a larger set,
the damage-associated molecular patterns (DAMPs) (see
recent review by Bianchi [2007]).
The data presented here show that a released factor en-
gages a triggering receptor on NK cells and thus support
a model for a ‘‘damage-induced recognition’’ (Matzinger,
2002) by factors released from tumor cells or accessory
cells (dendritic cells, macrophages).
EXPERIMENTAL PROCEDURES
Yeast Two-Hybrid Screening
We used a K562-derived cDNA library (BD Clontech, Germany, Heidel-
berg [HL4032AH]) and the yeast expression plasmids pGBT9 and
pGADT7 (BD Clontech) to identify NKp30 interaction partners. The
DNA encoding the NKp30 leader and extracellular domain (amino
acids 1–110, accession number gi 24475831) was amplified by the
polymerase chain reaction (PCR) from cDNA from the human NK line
NKL (Robertson et al., 1996). The PCR-generated fragment was
cloned into the yeast expression vector pGBT9 in-frame with the
GAL4-DNA-binding domain. The clones interacting with NKp30 were
sequenced and a gene bank search (NCBI blast) revealed the isolation
of BAT3-CT (accession number gi 149158691). The BAT3 cDNAs
either including or lacking the BAG domain were amplified by PCR
from K562-derived cDNA, cloned into pGADT7, and tested for NKp30
interaction. The BAT3 deletion constructs were generated either by
PCR amplification or by means of internal restriction sites. The DNA
fragment encoding NKp46 (amino acids 1–287, accession number gi
89363035) was amplified by PCR from NKL-derived cDNA and cloned
into pGBT9.
RT-PCR
BAT3 transcripts were amplified by RT-PCR with sequence-specific
primers (50TTCCCCAGCCCCTGGAA and 50TTGGGGAAACCCTGGG
GACTGT). The human tumor cDNA panel for the PCR was obtained
by BD, Clontech (pt3158).
Cells
We used the following cell lines: the human fibroblast kidney cell line
293T, the human colon carcinoma cell line LS174T, the human multiple
myeloma cell line RPMI8226, and the human NK cell line NKL (Robert-
son et al., 1996). NK cells were obtained from peripheral blood mono-
nuclear cells (PBMCs) from healthy-donor buffy coats by Ficoll-Paque
density gradient centrifugation with Leucosep columns from Greiner
bio-one (Solingen, Germany). Non-NK cells were depleted with the
NK Cell Isolation Kit and VarioMACS (Miltenyi, Bergisch Gladbach,
Germany). Separated polyclonal NK cells were cultivated in minimal
essential medium (MEM) alpha supplemented with 50 mg/mL penicillin,
50 mg/mL streptomycin, 10% fetal calf serum, and 10 U/mL recombi-
nant human IL-2 (R&D Systems, Wiesbaden, Germany) at 37C with
5% CO2. The cytokine release assay (Figure 4) was performed without
addition of IL-2.
Primary immature dendritic cells (iDCs) were obtained from adher-
end peripheral blood monocytes after incubation for 5 days in the pres-
ence of IL-4 and GM-CSF (R&D Systems, Wiesbaden Germany) at the
final concentrations of 20 ng ml1 and 50 ng ml1, respectively.
NKp30-Ig, CD30-Ig, and NKG2D-Ig Fusion Proteins
The sequence encoding the extracellular domain of NKp30 was ampli-
fied by PCR from NKL-derived cDNA and cloned into the expression
vector pCDNA3.1 (Invitrogen, Karlsruhe, Germany), which contained
the human IgG1 kappa leader sequence (N-terminal) and the genomic972 Immunity 27, 965–974, December 2007 ª2007 Elsevier IncDNA of the Fc portion of human IgG1 (C-terminal). The CD30 extra-
cellular sequence was inserted in-frame between the IgG1 kappa
leader and the genomic DNA of the Fc portion of human IgG1.
NKp30-Ig and CD30-Ig fusion proteins were purified from the super-
natants of transfected 293T cells with protein-G sepharose beads as
recommended by the manufacturer (Amersham Bioscience, Freiburg,
Germany). Recombinant NKG2D-Ig was purchased from R&D Sys-
tems, Wiesbaden, Germany.
Antibodies
We used the following primary antibodies: anti-NKp30 (sc-20477,
Santa Cruz Biotechnology, Heidelberg, Germany) for immunoblots;
anti-NKp30 (mAb1849, R&D Systems, Wiesbaden, Germany) for
FACS and blocking experiments; BH1-2A as anti-NKp30 isotype con-
trol (kindly provided by H. Stein, UK Berlin); anti-His (34660, QIAGEN,
Hilden, Germany); anti-HSP70 (SPA810, Biomol, Hamburg, Germany);
anti-LAMP2b (ab18529, Abcam, Germany); anti-BAT3 (ab37751, Ab-
cam); and the monoclonal CD30 antibody 5F11 (Borchmann et al.,
2003). The generation of the BAT3-specific rabbit antiserum (raised
against the COOH-terminal region as an antigen (NH2)-RKVKPQPPLS
DAYLSGMPAK) was described elsewhere (Desmots et al., 2005). The
FITC-labeled choleratoxin (c-1655) was purchased from Sigma-
Aldrich, Taufkirchen, Germany. The secondary antibodies were ob-
tained from Dianova GmbH, Hamburg, Germany.
BAT3 Mammalian Expression Constructs
DNA fragments encoding BAT3-CT and BAT3 were cloned into the ex-
pression vectors pCDNA3.1 and pCDNA3.1-His (Invitrogen, Karlsruhe,
Germany) in-frame with a C-terminal 6xhistidine tag (His)6 and into
pEGFP-C1 (BD Biosciences Clontech, Palo Alto, CA) in-frame with
the N-terminal eGFP sequence.
Immunoprecipitation and BAT3 Depletion
The expression constructs encoding histidine-tagged BAT3 and BAT3-
CT were transfected with lipofectamine (Invitrogen, Karlsruhe, Ger-
many) into 293T wild-type cells and 293T cells constitutively express-
ing NKp30-Ig. Cell lysates were prepared after 48 hr with lysis buffer
(50 mM Tris, 150 mM NaCl, 0.1% Triton X-100, 0.5% Sodium de-
oxcholate, 2 mM EDTA, and 0.1% SDS) containing cocktail protease
inhibitors (Amersham Bioscience), and precipitation was performed
with protein-G sepharose beads slurry (Amersham Bioscience) as
recommended. The eluates were used for immunoblotting with His
and Ig antibodies to detect His-tagged BAT3 proteins and NKp30-Ig,
respectively.
For depletion of BAT3, cells were harvested exposed to a nonlethal
heat shock and the supernatant was collected and incubated with two
rabbit polyclonal sera raised against BAT3 (serum 25 and 23; Desmots
et al., 2005) for 1 hr followed by incubation with protein-A beads over
night (buffering conditions were maintained with 103 Tris-Nacl). The
supernatant was used for immunoblotting to detect BAT3.
Immunofluorescence
The transfected target cells were cultured on glass slides and incu-
bated with NK cells (ratio 1:20) as indicated. The cells were fixed
with acetone before staining with monoclonal his antibody (QIAGEN),
monoclonal CD30 antibody (Borchmann et al., 2003), or FITC-labeled
choleratoxin (Sigma-Aldrich) followed by staining with labeled second-
ary antibodies. The antibodies were diluted in phosphate-buffered
saline with 10% serum.
Tumor Cell-Derived Supernatant and Purified BAT3
BAT3-transfected 293T cells were either left untreated or exposed to
a nonlethal heat shock. For the heat shock, 2 3 106 cells (eppendorf
tube) were incubated with 1 ml medium at 42C for 30 min followed
by a recovery period at 37C for 2 hr (BAT3-SN). BAT3 was purified
with NiNTA affinity chromatography according to QIAGEN, Hilden,
Germany (The QIAexpressionist, 2003) and dialyzed against PBS.
Membrane vesicles were prepared from the supernatant by three.
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BAT3 Release from Tumor Cells Activates NK Cellssuccessive centrifugations at 300 3 g (5 min), 1200 3 g (20 min), and
10,0003 g (30 min) to eliminate cells and debris, followed by centrifu-
gation for 1 hr at 100,0003 g. The exosome pellet was washed once in
a large volume of PBS, centrifuged at 100,000 3 g for 1 hr, and resus-
pended in PBS.
Expression and purification of the histidine-tagged control protein
DCoH is described elsewhere (Pogge von Strandmann et al., 2000).
Cytotoxicity Assays
The cytotoxicity was estimated in a standard 5 hr europium release as-
say in a 96-well micro titer plate in a total volume of 200 ml with 53 103
tumor target cells and different effector:target ratios. NK cells were in-
cubated with 50% serum for 30 min at 4C, washed, and incubated
with the monoclonal anti-NKp30 (R&D Systems, mAb1849) in the final
concentration of 10 mg ml1 for 1 hr at 4C to block NKp30. Blocking of
NKp30-Ig to BAT3-transfected cells was performed by incubating the
target cells with 15 mg ml1 NKp30-Ig for 30 min prior lysis. The block-
ing anti-BAT3 serum (rabbit) was used in a 1:1000 dilution. The spon-
taneous release did not exceed 25% of the maximum release.
Flow Cytometry
The binding of tumor cell-derived supernatant and anti-NKp30 mAb
was detected on primary NK cells. Cells were preincubated with super-
natant for 1 hr at 4C for blocking experiments. Binding of antibodies to
viable cells was analyzed on a FACSCalibur flow cytometer (Becton
Dickinson, Heidelberg, Germany).
IFN-g and TNF-a Assay
1–2 3 105 primary NK cells were incubated for 48 hr with medium or
supernatants derived from 293T cells either vector (mock) or BAT3-
transfected (BAT3-SN) and with purified BAT3 protein or purified
DCoH control protein (Pogge von Strandmann et al., 2000). Block-
ing monoclonal antibodies were used at a final concentration of
10 mg/ml, and the rabbit or chicken antisera were used 1:1000 diluted.
The NK cell-derived supernatants were analyzed (final concentration
1:5 diluted) with IFN-g and TNF-a ELISA Detection Kits (Becton Dick-
enson, Heidelberg, Germany). The absorbance of the plates was
measured with the ELISA reader m-Quant (Bio-Tek, Bad Friedrichshall,
Germany) in parallel with the measurement of the corresponding
standards.
Multiple Myeloma Xenograft Model
RPMI8226 cells (5 3 106) resuspended in 200 ml PBS were injected
subcutaneously into CD1 nude mice (Charles River, Sulzfeld, Ger-
many) to establish tumors. Peripheral blood lymphocytes were
isolated from healthy donors by Ficoll-Paque density gradient centri-
fugation with Leucosep columns, mixed with rabbit control serum or
a BAT3-specific antiserum (rabbit, 1:20 dilution), and injected subcuta-
neously ((53 106)/200 ml per animal). The experiments were performed
in accordance with the institutional and national regulations (permis-
sion: 50.203.2-K17, 4/02).
Statistics
The results of the NK cell-activation assays are indicated as means ±
standard deviation. Significance was calculated with the GraphPad-
Prism software (San Diego, CA) with the Student’s t test.
Supplemental Data
Three figures are available at http://www.immunity.com/cgi/content/
full/27/6/965/DC1/.
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